Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy

Launched by SPAULDING REHABILITATION HOSPITAL · Nov 11, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into a treatment called extracorporeal shockwave therapy (ESWT) for people who have knee osteoarthritis (OA) following an anterior cruciate ligament (ACL) injury. Specifically, the study is focused on current or former athletes who had ACL reconstruction surgery at least a year ago and are experiencing knee pain and difficulty moving their knee. The goal is to see how effective ESWT is in reducing pain, improving knee function, and helping with overall joint health.

To join this study, participants should be between 18 and 55 years old, have mild to moderate knee osteoarthritis confirmed by a doctor, and have had ACL reconstruction surgery using a specific technique. Those who have had recent knee injections, are pregnant, or have certain medical conditions may not be eligible. Participants will receive the ESWT treatment and will be monitored for changes in their knee pain, movement, and overall function. This is an excellent opportunity for individuals looking for new ways to manage knee pain and improve their quality of life after an ACL injury.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of mild to moderate PTOA based on clinical diagnosis and confirmation with radiographic evidence by a medical professional prior to study enrollment
• • Previous ACL reconstruction using patellar-tendon-bone autograft in the knee with PTOA
• • Minimum of one year following ACL reconstruction surgery
• • Between ages of 18 and 55
• • No clear contraindication to complete protocol including mechanical symptoms which would limit ability to complete the study
• • Score on KOOS pain subscale of \< 72
• • Primary pain is coming from the knee
• Exclusion Criteria:
• • Have previously received injections to the knee joint within the past 3 months
• • Women who are pregnant or those who are planning to become pregnant. This is due to the fact that pregnancy will reduce participants activity after the treatment and the safety concerns related to shockwave treatment. - Participants with neuropathy affecting sensation to pain
• • Participants with a known underlying cardiac disease that could be affected by shockwave therapy
• • Chronic rheumatological conditions, immunodeficiency, severe asthma, connective tissue disorder (i.e. Ehlers-Danlos Syndrome), or other medical conditions (ex. active malignancy, severe asthma) outside of PTOA that are known to impact inflammatory state or requiring chronic use of oral or intravenous immune modulatory medications. Asthma requiring use of inhalers only is not an exclusion criteria
• • Neuropathy diagnosis that can affect response to pain
• • No active use of oral steroids or anti-inflammatories at the time of enrollment
• • Have bilateral ACL injury or reconstruction surgery, or have had ACL revision surgery
• • No active malignancy and at least five years in remission
• • Previous ESWT treatment using study treatment devices for management of knee osteoarthritis
• • Have a pacemaker, bone screws, or any other metal implants that would prohibit participation in an MRI scan or EWST
• • Non-English speaking individuals